PURPOSE: The purpose of the study is to estimate the trends in drug prescriptions and the hospitalization rates for lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) in real-life clinical practice, using information deriving from administrative databases of the Italian health care system. METHODS: Prescription data on approximately 1,500,000 men over 40 were examined, and prescribed boxes of alpha-blockers (ABs) and/or 5 alpha reductase inhibitors (5ARI) were calculated for 5 consecutive years, from 2004 to 2008. Annual use prevalence and incidence rates for each drug class and for the combination therapy (CT) were calculated according to age for the entire study period. Hospitalization rates for reasons related to LUTS/BPH were also evaluated for the same time period. RESULTS: The overall distribution of drugs for LUTS/BPH, in terms of number of boxes prescribed, increased by 43 %. This increase was accounted for by both classes of drugs although it was greater for 5ARI than for AB (+49 vs +41 %). The prevalence of CT showed a substantial increase to almost 25 % in patients aged ≥75. Hospitalization rate for BPH/LUTS-related reasons decreased during the study period (8 and 3 % per year for non-surgical and surgical reasons, respectively). CONCLUSIONS: The prevalence of the use of drugs prescribed for LUTS/BPH has steadily increased. An increase in terms of prescribed boxes was observed for both classes of drugs, even though the increase was greater for 5ARIs. The reduction in the hospitalization rates needs additional researches.
PURPOSE: The purpose of the study is to estimate the trends in drug prescriptions and the hospitalization rates for lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) in real-life clinical practice, using information deriving from administrative databases of the Italian health care system. METHODS: Prescription data on approximately 1,500,000 men over 40 were examined, and prescribed boxes of alpha-blockers (ABs) and/or 5 alpha reductase inhibitors (5ARI) were calculated for 5 consecutive years, from 2004 to 2008. Annual use prevalence and incidence rates for each drug class and for the combination therapy (CT) were calculated according to age for the entire study period. Hospitalization rates for reasons related to LUTS/BPH were also evaluated for the same time period. RESULTS: The overall distribution of drugs for LUTS/BPH, in terms of number of boxes prescribed, increased by 43 %. This increase was accounted for by both classes of drugs although it was greater for 5ARI than for AB (+49 vs +41 %). The prevalence of CT showed a substantial increase to almost 25 % in patients aged ≥75. Hospitalization rate for BPH/LUTS-related reasons decreased during the study period (8 and 3 % per year for non-surgical and surgical reasons, respectively). CONCLUSIONS: The prevalence of the use of drugs prescribed for LUTS/BPH has steadily increased. An increase in terms of prescribed boxes was observed for both classes of drugs, even though the increase was greater for 5ARIs. The reduction in the hospitalization rates needs additional researches.
Authors: Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei Journal: J Urol Date: 2011-03-21 Impact factor: 7.450
Authors: P C Souverein; M M van Riemsdijk; J J M C H de la Rosette; P C E Opdam; H G M Leufkens Journal: Eur Urol Date: 2004-12-29 Impact factor: 20.096
Authors: Seth A Strope; Sean P Elliott; Christopher S Saigal; Alex Smith; Timothy J Wilt; John T Wei Journal: Urology Date: 2011-05-23 Impact factor: 2.649
Authors: J D McConnell; R Bruskewitz; P Walsh; G Andriole; M Lieber; H L Holtgrewe; P Albertsen; C G Roehrborn; J C Nickel; D Z Wang; A M Taylor; J Waldstreicher Journal: N Engl J Med Date: 1998-02-26 Impact factor: 91.245
Authors: Raymond Rosen; Jens Altwein; Peter Boyle; Roger S Kirby; B Lukacs; Eric Meuleman; Michael P O'Leary; Paolo Puppo; Chris Robertson; Francois Giuliano Journal: Eur Urol Date: 2003-12 Impact factor: 20.096
Authors: Mohamed Bishr; Katharina Boehm; Vincent Trudeau; Zhe Tian; Paolo Dell'Oglio; Jonas Schiffmann; Claudio Jeldres; Maxine Sun; Sharokh F Shariat; Markus Graefen; Fred Saad; Pierre I Karakiewicz Journal: Can Urol Assoc J Date: 2016 Jan-Feb Impact factor: 1.862
Authors: Antonio Alcaraz; Joaquín Carballido-Rodríguez; Miguel Unda-Urzaiz; Rafael Medina-López; José L Ruiz-Cerdá; Federico Rodríguez-Rubio; Darío García-Rojo; Francisco J Brenes-Bermúdez; José M Cózar-Olmo; Víctor Baena-González; José Manasanch Journal: Int Urol Nephrol Date: 2016-01-25 Impact factor: 2.370